The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced the results of a Phase 3 trial involving MDMA-assisted therapy for people suffering from chronic and severe PTSD. The results were ‘highly statistically significant,’ according to MAPS, which reports that 67-percent of the participants who underwent three of these MDMA-assisted therapy sessions saw enough improvement that they no longer met the …
The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced the results of a Phase 3 trial involving MDMA-assisted therapy for people suffering from chronic and severe PTSD. The results were ‘highly statistically significant,’ according to MAPS, which reports that 67-percent of the participants who underwent three of these MDMA-assisted therapy sessions saw enough improvement that they no longer met the …
Share this Article
Recommended